Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 09 Oct 2024 According to a Gilead Sciences media release, three-year outcomes from this study will be presented at at IDWeek 2024, taking place from October 16-19.
  • 06 Mar 2024 Results analyzing the effect of ART on selected biomarkers of inflammation and immune activation presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
  • 26 Oct 2022 Results of pooled analysis from Study 1489 and Stduy 1490 assessing 96-week (W) outcomes on bictegravir/emtricitabine/tenofovir alafe-namide (B/F/TAF) in an open-label extension (OLE) that followed144W of blinded DTG-based treatment in two phase III studies ofPWHIV initiating treatment presented at the 16th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top